<Disease><Name>ETHYLMALONIC ENCEPHALOPATHY, EE (EPEMA)</Name><Synonym>METABOLIC ENCEPHALOPATHY (EPEMA); EPEMA SYNDROME; ETHE1</Synonym><OMIM><Number>602473</Number><URL>http://omim.org/entry/602473</URL></OMIM><Orphanet><Number>51188</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=51188</URL></Orphanet><Protein><Number>persulfide dioxygenase ETHE1, mitochondrial</Number><URL>http://www.uniprot.org/uniprot/O95571</URL></Protein><ExPASy><Number /><URL /></ExPASy><Gene>19q13.31</Gene><ICD>G31.81</ICD><Summary>rare (&lt;1:200000) ;autosomal recessive ;mutations in ETHE1 gene</Summary><Symptoms><symtomp><id>3786</id><symptom>acrocyanosis</symptom><category>SKIN</category></symtomp><symtomp><id>1942</id><symptom>ataxia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1982</id><symptom>diarrhea</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>1946</id><symptom>dystonia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2423</id><symptom>early death</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2105</id><symptom>encephalopathy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3709</id><symptom>epilepsy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1969</id><symptom>extrapyramidal signs</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2095</id><symptom>failure to thrive</symptom><category>GASTROINTESTINAL SYSTEM | GENERAL TOPICS</category></symtomp><symtomp><id>2433</id><symptom>hearing defect, deafness</symptom><category>EARS | NERVOUS SYSTEM</category></symtomp><symtomp><id>2274</id><symptom>hematuria</symptom><category>GENERAL TOPICS | GENITOURINARY TRACT</category></symtomp><symtomp><id>3814</id><symptom>hemorrhagic diarrhea, chronic</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>1897</id><symptom>hypotonia</symptom><category>MUSCLES | NERVOUS SYSTEM</category></symtomp><symtomp><id>1951</id><symptom>irritability</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3197</id><symptom>lactic acidosis</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>2424</id><symptom>mental retardation</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2213</id><symptom>MRI, brain, abnormalities [-]</symptom><category>LABORATORY FINDINGS | NERVOUS SYSTEM</category></symtomp><symtomp><id>2402</id><symptom>myelopathy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2505</id><symptom>onset, infancy / infancy</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2339</id><symptom>ophthalmoplegia</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>2331</id><symptom>peripheral vascular disease</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>2215</id><symptom>petechiae</symptom><category>SKIN</category></symtomp><symtomp><id>1919</id><symptom>progressive neurologic defect</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3680</id><symptom>psychomotor retardation</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1970</id><symptom>pyramidal signs</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2143</id><symptom>respiratory insufficiency / respiratory failure</symptom><category>LUNG OR RESPIRATORY SYSTEM</category></symtomp><symtomp><id>1943</id><symptom>seizures</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>1974</id><symptom>spastic diplegia/quadriplegia/tetraplegia</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>2263</id><symptom>strokelike episodes</symptom><category>NERVOUS SYSTEM</category></symtomp></Symptoms><Metabolites><metabolite><id>1615</id><name>Ethylmalonic acid</name><specimen>urine</specimen><value>increased</value><min>1.20</min><max>5.80</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1663</id><name>2-Methylsuccinic acid</name><specimen>urine</specimen><value>increased</value><min>0.70</min><max>9.90</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1768</id><name>Isobutyrylglycine</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>29.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1808</id><name>Ethylmalonic acid</name><specimen>urine</specimen><value>increased</value><min>20.00</min><max>42.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>108</id><name>2-Methylbutyrylglycine</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>2.00</max><unit>mmol/mol creatinine</unit><age>ALL</age><method>GCMS</method><comment /></metabolite><metabolite><id>1568</id><name>2-Methylbutyrylglycine</name><specimen>urine</specimen><value>increased</value><min>1.20</min><max>3.30</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1219</id><name>Butyryl/Isobutyrylcarnitine (C4)</name><specimen>blood</specimen><value>increased</value><min>0.31</min><max>1.66</max><unit>&#181;mol/l</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>1220</id><name>Butyryl/Isobutyrylcarnitine (C4)</name><specimen>serum</specimen><value>increased</value><min>0.53</min><max>2.81</max><unit>&#181;mol/l</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>338</id><name>Butyrylglycine</name><specimen>urine</specimen><value>increased</value><min>0.01</min><max>0.12</max><unit>mmol/mol creatinine</unit><age>all</age><method /><comment /></metabolite><metabolite><id>749</id><name>Butyrylglycine</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>2.00</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>445</id><name>Ethylmalonic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>9.00</max><unit>mmol/mol creatinine</unit><age>ALL</age><method /><comment /></metabolite><metabolite><id>614</id><name>Ethylmalonic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>19.00</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>615</id><name>Ethylmalonic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>11.00</max><unit>mmol/mol creatinine</unit><age>infancy</age><method /><comment /></metabolite><metabolite><id>616</id><name>Ethylmalonic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>15.00</max><unit>mmol/mol creatinine</unit><age>childhood 4-6y</age><method /><comment /></metabolite><metabolite><id>617</id><name>Ethylmalonic acid</name><specimen>urine</specimen><value>increased</value><min>1.00</min><max>5.00</max><unit>mmol/mol creatinine</unit><age>childhood 6-12y</age><method /><comment /></metabolite><metabolite><id>618</id><name>Ethylmalonic acid</name><specimen>urine</specimen><value>increased</value><min>2.00</min><max>10.00</max><unit>mmol/mol creatinine</unit><age>adolescence</age><method /><comment /></metabolite><metabolite><id>107</id><name>Isobutyrylglycine</name><specimen>urine</specimen><value>increased</value><min>1.00</min><max>4.00</max><unit>mmol/mol creatinine</unit><age>childhood</age><method /><comment /></metabolite><metabolite><id>1334</id><name>Isobutyrylglycine</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>3.70</max><unit>mmol/mol creatinine</unit><age>ALL</age><method>GCMS</method><comment /></metabolite><metabolite><id>1632</id><name>Isovaleroylglycine</name><specimen>urine</specimen><value>increased</value><min>0.40</min><max>4.00</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1780</id><name>Isovaleroylglycine</name><specimen>urine</specimen><value>increased</value><min>2.00</min><max>5.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>1</id><name>Isovaleroylglycine</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>9.00</max><unit>mmol/mol creatinine</unit><age>ALL</age><method>GCMS</method><comment /></metabolite><metabolite><id>1346</id><name>Isovaleroylglycine</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>0.80</max><unit>mmol/mol creatinine</unit><age>infancy/childhood</age><method /><comment /></metabolite><metabolite><id>767</id><name>L-Lactic acid</name><specimen>jejunal biopsy</specimen><value>increased</value><min>    </min><max>100.00</max><unit>% activity</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>21</id><name>L-Lactic acid</name><specimen>urine</specimen><value>increased</value><min>3.50</min><max>29.30</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>536</id><name>L-Lactic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>197.00</max><unit>mmol/mol creatinine</unit><age>ALL</age><method /><comment /></metabolite><metabolite><id>537</id><name>L-Lactic acid</name><specimen>urine</specimen><value>increased</value><min>40.00</min><max>326.00</max><unit>mmol/mol creatinine</unit><age>infancy</age><method /><comment /></metabolite><metabolite><id>538</id><name>L-Lactic acid</name><specimen>urine</specimen><value>increased</value><min>5.00</min><max>117.00</max><unit>mmol/mol creatinine</unit><age>childhood 6-12y</age><method /><comment /></metabolite><metabolite><id>539</id><name>L-Lactic acid</name><specimen>urine</specimen><value>increased</value><min>6.00</min><max>64.00</max><unit>mmol/mol creatinine</unit><age>childhood</age><method /><comment /></metabolite><metabolite><id>1411</id><name>L-Lactic acid</name><specimen>urine</specimen><value>increased</value><min>100.00</min><max>152.00</max><unit>mmol/mol creatinine</unit><age>newborn 1-7d</age><method /><comment /></metabolite><metabolite><id>330</id><name>L-Lactic acid</name><specimen>blood</specimen><value>increased</value><min>0.70</min><max>3.30</max><unit>mmol/l</unit><age>infant</age><method /><comment /></metabolite><metabolite><id>339</id><name>L-Lactic acid</name><specimen>cerebrospinal fluid</specimen><value>increased</value><min>0.50</min><max>1.80</max><unit>mmol/l</unit><age>Childhood</age><method /><comment /></metabolite><metabolite><id>469</id><name>L-Lactic acid</name><specimen>blood</specimen><value>increased</value><min>0.90</min><max>1.80</max><unit>mmol/l</unit><age>child</age><method /><comment /></metabolite><metabolite><id>208</id><name>L-Lactic acid</name><specimen>blood</specimen><value>increased</value><min>0.80</min><max>1.50</max><unit>mmol/l</unit><age>Childhood</age><method /><comment /></metabolite><metabolite><id>211</id><name>L-Lactic acid</name><specimen>blood</specimen><value>increased</value><min>0.70</min><max>1.90</max><unit>mmol/l</unit><age>Adulthood</age><method /><comment /></metabolite><metabolite><id>214</id><name>L-Lactic acid</name><specimen>blood</specimen><value>increased</value><min>1.00</min><max>2.30</max><unit>mmol/l</unit><age>infant</age><method /><comment /></metabolite><metabolite><id>206</id><name>L-Lactic acid</name><specimen>blood</specimen><value>increased</value><min>0.90</min><max>2.00</max><unit>mmol/l</unit><age>Infancy</age><method /><comment /></metabolite><metabolite><id>209</id><name>L-Lactic acid</name><specimen>blood</specimen><value>increased</value><min>0.50</min><max>1.60</max><unit>mmol/l</unit><age>child</age><method /><comment /></metabolite><metabolite><id>212</id><name>L-Lactic acid</name><specimen>blood</specimen><value>increased</value><min>0.60</min><max>0.90</max><unit>mmol/l</unit><age>adult</age><method /><comment /></metabolite><metabolite><id>202</id><name>L-Lactic acid</name><specimen>blood</specimen><value>increased</value><min>0.80</min><max>1.50</max><unit>mmol/l</unit><age>infant</age><method /><comment /></metabolite><metabolite><id>210</id><name>L-Lactic acid</name><specimen>blood</specimen><value>increased</value><min>0.70</min><max>1.90</max><unit>mmol/l</unit><age>child</age><method /><comment /></metabolite><metabolite><id>213</id><name>L-Lactic acid</name><specimen>blood</specimen><value>increased</value><min>0.40</min><max>1.00</max><unit>mmol/l</unit><age>adult</age><method /><comment /></metabolite><metabolite><id>1137</id><name>L-Lactic acid</name><specimen>blood</specimen><value>increased</value><min>0.40</min><max>0.90</max><unit>mmol/l</unit><age>7-15 years</age><method /><comment /></metabolite><metabolite><id>1136</id><name>L-Lactic acid</name><specimen>blood</specimen><value>increased</value><min>0.70</min><max>1.60</max><unit>mmol/l</unit><age>1-7 years</age><method /><comment /></metabolite><metabolite><id>203</id><name>L-Lactic acid</name><specimen>blood</specimen><value>increased</value><min>0.90</min><max>1.80</max><unit>mmol/l</unit><age>child</age><method /><comment /></metabolite><metabolite><id>204</id><name>L-Lactic acid</name><specimen>blood</specimen><value>increased</value><min>1.00</min><max>1.50</max><unit>mmol/l</unit><age>adult</age><method /><comment /></metabolite><metabolite><id>207</id><name>L-Lactic acid</name><specimen>blood</specimen><value>increased</value><min>2.00</min><max>3.00</max><unit>mmol/l</unit><age>infant</age><method /><comment /></metabolite><metabolite><id>1813</id><name>L-Lactic acid</name><specimen>urine</specimen><value>increased</value><min>45.00</min><max>410.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>105</id><name>2-Methylsuccinic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>3.00</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method /><comment /></metabolite><metabolite><id>619</id><name>2-Methylsuccinic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>6.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method /><comment /></metabolite><metabolite><id>620</id><name>2-Methylsuccinic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>9.00</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method /><comment /></metabolite><metabolite><id>623</id><name>2-Methylsuccinic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>2.00</max><unit>mmol/mol creatinine</unit><age>ALL</age><method /><comment /></metabolite><metabolite><id>456</id><name>Thiosulfate</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>55.00</max><unit>mmol/mol creatinine</unit><age>infancy</age><method /><comment /></metabolite></Metabolites><Literatures><literature><id>5000</id><title>Neurological and Vascular Manifestations of Ethylmalonic Encephalopathy</title><author>Tavasoli AR,</author><journal>Iran J Child Neurol</journal><year>2017</year><book /><volume>11</volume><number>2</number><pages>57-60</pages><co_aut>et al.</co_aut></literature><literature><id>4661</id><title>Successful treatment of a patient with ethylmalonic encephalopathy by intravenous N-acetylcysteine</title><author>K&#305;l&#305;c M,</author><journal>Metab Brain Dis</journal><year>2017</year><book /><volume>32</volume><number>2</number><pages>293-296</pages><co_aut>et al.</co_aut></literature><literature><id>4662</id><title>Bioenergetics dysfunction, mitochondrial permeability transition pore opening and lipid peroxidation induced by hydrogen sulfid</title><author>Cardoso GMF,</author><journal>Biochim Biophys Acta</journal><year>2017</year><book /><volume>1863</volume><number>9</number><pages>2192-2201</pages><co_aut>et al.</co_aut></literature><literature><id>4441</id><title>Diffusion restriction in ethylmalonic encephalopathy - An imaging evidence of the pathophysiology of the disease</title><author>Bhat MD,</author><journal>Brain Dev</journal><year>2016</year><book /><volume>38</volume><number>8</number><pages>768-771</pages><co_aut>et al.</co_aut></literature><literature><id>4442</id><title>Untargeted Metabolomics Analysis Reveals a Link between ETHE1-Mediated Disruptive Redox State and Altered Metabolic Regulation&lt;</title><author>Sahebekhtiari N,</author><journal>J Proteome Res</journal><year>2016</year><book /><volume>15</volume><number>5</number><pages>1630-1638</pages><co_aut>et al.</co_aut></literature><literature><id>4663</id><title>Liver transplant in ethylmalonic encephalopathy: a new treatment for an otherwise fatal disease</title><author>Dionisi-Vici C,</author><journal>Brain</journal><year>2016</year><book /><volume>139</volume><number>4</number><pages>1045-1051</pages><co_aut>et al.</co_aut></literature><literature><id>3272</id><title>Importance of acrocyanosis in delayed walking</title><author>Yis U,</author><journal>J Pediatr Neurosci</journal><year>2015</year><book /><volume>10</volume><number>1</number><pages>80-81</pages><co_aut>et al.</co_aut></literature><literature><id>3273</id><title>Crystal structure of human persulfide dioxygenase: structural basis of ethylmalonic encephalopathy</title><author>Pettinati I,</author><journal>Hum Mol Genet</journal><year>2015</year><book /><volume>24</volume><number>9</number><pages>2458-2469</pages><co_aut>et al.</co_aut></literature><literature><id>3540</id><title>Mitochondrial diseases caused by toxic compound accumulation: from etiopathology to therapeutic approaches.</title><author>Di Meo I,</author><journal>EMBO Mol Med</journal><year>2015</year><book /><volume>7</volume><number>10</number><pages>1257-1266</pages><co_aut>Lamperti C1, Tiranti V</co_aut></literature><literature><id>4664</id><title>Severe early onset ethylmalonic encephalopathy with West syndrome</title><author>Papetti L,</author><journal>Metab Brain Dis</journal><year>2015</year><book /><volume>30</volume><number>6</number><pages>1537-1545</pages><co_aut>et al.</co_aut></literature><literature><id>3274</id><title>Ethylmalonic encephalopathy ETHE1 R163W/R163Q mutations alter protein stability and redox properties of the iron centre</title><author>Henriques BJ,</author><journal>PLoS One. 2014</journal><year>2014</year><book /><volume>9</volume><number>9</number><pages /><co_aut>et al.</co_aut></literature><literature><id>3275</id><title>Altered sulfide (H(2)S) metabolism in ethylmalonic encephalopathy</title><author>Tiranti V,</author><journal>Cold Spring Harb Perspect Biol</journal><year>2013</year><book /><volume>5</volume><number>1</number><pages /><co_aut>Zeviani M</co_aut></literature><literature><id>3277</id><title>An infant with ethylmalonic encephalopathy masquerading as a hematologic disorder</title><author>Pavlou E,</author><journal>J Child Neurol</journal><year>2013</year><book /><volume>28</volume><number>5</number><pages>668-671</pages><co_aut>et al.</co_aut></literature><literature><id>3127</id><title>Update on clinical aspects and treatment of selected vitamin-responsive disorders II (riboflavin and CoQ 10)</title><author>Horvath R</author><journal>J Inherit Metab Dis</journal><year>2012</year><book /><volume>35</volume><number>4</number><pages>679-687</pages><co_aut /></literature><literature><id>3276</id><title>Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy</title><author>Di Meo I,</author><journal>EMBO Mol Med</journal><year>2012</year><book /><volume>4</volume><number>9</number><pages>1008-1014</pages><co_aut>et al.</co_aut></literature><literature><id>6076</id><title>Ethylmalonic encephalopathy: application of improved biochemical and molecular diagnostic approaches</title><author>Drousiotou A,</author><journal>Clin Genet</journal><year>2011</year><book /><volume>79</volume><number>4</number><pages>385-390</pages><co_aut>et al.</co_aut></literature><literature><id>3039</id><title>Combined treatment with oral metronidazole and N-acetylcysteine is effective in ethylmalonic encephalopathy</title><author>Viscomi C,</author><journal>Nat Med</journal><year>2010</year><book /><volume>16</volume><number>8</number><pages>869-871</pages><co_aut>et al.</co_aut></literature><literature><id>3040</id><title>Chronic Exposure to Sulfide causes Accelerated Degradation of Cytochrome c oxidase in Ethylmalonic Encephalopathy</title><author>Di Meo I,</author><journal>Antioxid Redox Signal</journal><year>2010</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>3041</id><title>Ethylmalonic encephalopathy: application of improved biochemical and molecular diagnostic approaches</title><author>Drousiotou A,</author><journal>Clin Genet</journal><year>2010</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>2845</id><title>Clinical Heterogeneity in Ethylmalonic Encephalopathy</title><author>Pigeon N,</author><journal>J Child Neurol</journal><year>2009</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>3042</id><title>Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy</title><author>Tiranti V,</author><journal>Nat Med</journal><year>2009</year><book /><volume>15</volume><number>2</number><pages>200-205</pages><co_aut>et al.</co_aut></literature><literature><id>4665</id><title>Identification of new mutations in the ETHE1 gene in a cohort of 14 patients presenting with ethylmalonic encephalopathy</title><author>Mineri R,</author><journal>J Med Genet</journal><year>2008</year><book /><volume>45</volume><number>7</number><pages>473-478</pages><co_aut>et al.</co_aut></literature><literature><id>2739</id><title>Ethylmalonic encephalopathy: clinical and biochemical observations</title><author>Zafeiriou DI</author><journal>Neuropediatrics</journal><year>2007</year><book /><volume>38</volume><number>2</number><pages>78-82</pages><co_aut>et al.</co_aut></literature><literature><id>2740</id><title>A case of ethylmalonic encephalopathy with atypical clinical and biochemical presentation</title><author>Di Rocco M</author><journal>Mol Genet Metab</journal><year>2006</year><book /><volume>89</volume><number>4</number><pages>395-397</pages><co_aut>et al.</co_aut></literature><literature><id>2741</id><title>ETHE1 mutations are specific to ethylmalonic encephalopathy</title><author>Tiranti V</author><journal>J Med Genet</journal><year>2006</year><book /><volume>43</volume><number>3</number><pages>340-346</pages><co_aut>et al.</co_aut></literature><literature><id>4666</id><title>Persistent increase of plasma butyryl/isobutyrylcarnitine concentrations as marker of SCAD defect and ethylmalonic encephalopat</title><author>Merinero B,</author><journal>J Inherit Metab Dis</journal><year>2006</year><book /><volume>29</volume><number>5</number><pages>685</pages><co_aut>et al.</co_aut></literature><literature><id>2381</id><title>Acute metabolic encephalopathy: an introduction</title><author>Leonard JV</author><journal>J Inherit Metab Dis</journal><year>2005</year><book /><volume>28</volume><number>3</number><pages>403-406</pages><co_aut /></literature><literature><id>2504</id><title>Ethylmalonic encephalopathy is caused by mutations in ETHE1, a gene encoding a mitochondrial matrix protein</title><author>Tiranti V</author><journal>Am J Hum Genet</journal><year>2004</year><book /><volume>74</volume><number>2</number><pages>239-252</pages><co_aut>et al.</co_aut></literature><literature><id>2505</id><title>The role of methionine in ethylmalonic encephalopathy with petechiae</title><author>McGowan KA</author><journal>Arch Neurol</journal><year>2004</year><book /><volume>61</volume><number>4</number><pages>570-574</pages><co_aut>et al.</co_aut></literature><literature><id>1318</id><title>G protein diseases: newly recognized causes of metabolic encephalopathy</title><author>Jaeken JC</author><journal>Eur J Paediatr Neurol</journal><year>2003</year><book /><volume>7</volume><number>5</number><pages>211-215</pages><co_aut>et al.</co_aut></literature><literature><id>1319</id><title>Mitochondrial encephalopathy</title><author>Longo N</author><journal>Neurol Clin</journal><year>2003</year><book /><volume>21</volume><number>4</number><pages>817-831</pages><co_aut /></literature><literature><id>910</id><title>Central nervous system malformations in ethylmalonic encephalopathy</title><author>Nowaczyk MJ</author><journal>Genet</journal><year>1998</year><book /><volume>75</volume><number>0</number><pages>292-296</pages><co_aut>et al.</co_aut></literature><literature><id>764</id><title>Syndrome of encephalopathy. petechiae, and ethylmalonic aciduria</title><author>Garc&#237;a-Silva MT</author><journal>Pediatr Neurol</journal><year>1997</year><book /><volume>17</volume><number>0</number><pages>165-170</pages><co_aut>et al.</co_aut></literature><literature><id>200</id><title>Enzephalopathie, rezidivierende Diarrhoen und Vasopathie mit typischer Organoazidurie: eine neue Stoffwechselerkrankung als Folge einer Mutation im ETF/ETF-QO-Protein-Gen?</title><author>Trefz FK</author><journal>10. Jahrestagung der APS in Fulda</journal><year>1996</year><book>8.-10.2.96</book><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>19</id><title>A new syndrome with ethylmalonic aciduria and normal fatty acid oxidation in fibroblasts</title><author>Burlina AB</author><journal>J Pediatr</journal><year>1994</year><book /><volume>124</volume><number>1</number><pages>79-86</pages><co_aut>Dionisi-Vici C, Bennett MJ, Gibson KM, Servidei S, Bertini E, Hale DE, Schmidt-Sommerfeld E, Sabetta G, Zacchello F, Rin</co_aut></literature><literature><id>762</id><title>Muscle cytochrome c oxidase deficiency in two italian patients with ethylmalonic aciduria and peculiar clinical phenotype</title><author>Garavaglia B</author><journal>J Inherit Metab Dis</journal><year>1994</year><book /><volume>17</volume><number>0</number><pages>301-303</pages><co_aut>et al.</co_aut></literature><literature><id>763</id><title>Ethylmalonic aciduria: an organic acidemia with CNS involvement and vasculopathy</title><author>Ozand PT</author><journal>Brain Dev Suppl</journal><year>1994</year><book /><volume>16</volume><number>0</number><pages>12-22</pages><co_aut>et al.</co_aut></literature><literature><id>11</id><title>Ethylmalonic aciduria associated with progressive neurological disease and partial cytochrome c oxidase deficiency</title><author>Lehnert W</author><journal>J Inh Met Dis</journal><year>1993</year><book /><volume>16</volume><number>0</number><pages>557-559</pages><co_aut>Ruitenbeek W</co_aut></literature></Literatures></Disease>